At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02565 PEGBIO CO-B
Market Closed 05-29 16:08:26
8.630
-0.200
-2.27%
High9.700Low8.450Vol30.84M
Open9.000D1 Closing8.830Amplitude14.16%
Mkt Cap3.37BTradable Cap2.45BTotal Shares391.00M
T/O281.32MT/O Rate10.86%Tradable Shares284.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
PEGBIO CO-B's GLP-1 Agonist Vepetide Injection Included in 2026 National Reimbursement Drug List Pre-Communication Process
Stock News  ·  05-28 18:20
PEGBIO CO-B's GLP-1 Agonist Vepetide Injection Included in 2026 National Reimbursement Drug List Pre-Communication Process
Stock Track | PegBio Pharma Soars 15.53% Intraday on Technical Rebound After IPO Lock-up Expiry Selloff
Stock Track  ·  05-28 09:34
Stock Track | PegBio Pharma Soars 15.53% Intraday on Technical Rebound After IPO Lock-up Expiry Selloff
Movement Alert｜PegBio Pharma Rises 10.77% in Regular Trading, Technical Rebound After IPO Lock-up Expiry Selloff
Market Focus  ·  05-28 09:32
Movement Alert｜PegBio Pharma Rises 10.77% in Regular Trading, Technical Rebound After IPO Lock-up Expiry Selloff
Movement Alert｜PegBio Pharma Intraday Decline 15.99% in Regular Trading, Lock-Up Expiry on IPO Anniversary Triggers Selling Pressure
Market Focus  ·  05-27
Movement Alert｜PegBio Pharma Intraday Decline 15.99% in Regular Trading, Lock-Up Expiry on IPO Anniversary Triggers Selling Pressure
Stock Track | PegBio Soars 18.76% Intraday on Continued GLP-1 Drug Commercialization Momentum
Stock Track  ·  05-22
Stock Track | PegBio Soars 18.76% Intraday on Continued GLP-1 Drug Commercialization Momentum
Movement Alert｜PegBio Rises 7.54% in Regular Trading, Rebounding After Pullback as GLP-1 Drug Commercialization Momentum Continues
Market Focus  ·  05-22
Movement Alert｜PegBio Rises 7.54% in Regular Trading, Rebounding After Pullback as GLP-1 Drug Commercialization Momentum Continues
Stock Track | PegBio Plummets 6.96% Intraday Amid Lock-Up Expiry Concerns Following Partnership Rally
Stock Track  ·  05-21
Stock Track | PegBio Plummets 6.96% Intraday Amid Lock-Up Expiry Concerns Following Partnership Rally
Movement Alert｜PegBio Falls 5.14% in Regular Trading, Pullback Continues Amid Lock-Up Expiry Concerns Following Multi-Day Rally
Market Focus  ·  05-21
Movement Alert｜PegBio Falls 5.14% in Regular Trading, Pullback Continues Amid Lock-Up Expiry Concerns Following Multi-Day Rally
Stock Track | PegBio Soars 6.86% Intraday on GLP-1 Drug Commercialization Deals
Stock Track  ·  05-20
Stock Track | PegBio Soars 6.86% Intraday on GLP-1 Drug Commercialization Deals
Movement Alert｜PegBio Co Ltd Rises 8.37% in Regular Trading, Extending Gains on GLP-1 Drug Commercialization Momentum
Market Focus  ·  05-20
Movement Alert｜PegBio Co Ltd Rises 8.37% in Regular Trading, Extending Gains on GLP-1 Drug Commercialization Momentum
PEGBIO CO-B Nominates Liao Yilin as Independent Non-Executive Director Candidate
Stock News  ·  05-19
PEGBIO CO-B Nominates Liao Yilin as Independent Non-Executive Director Candidate
Pegbio files directors list with Hong Kong Stock Exchange
Reuters  ·  05-19
Pegbio files directors list with Hong Kong Stock Exchange
PegBio: INED Resignation Triggers Temporary Rule Breach; New Candidate Nominated to Restore Compliance
Bulletin Express  ·  05-19
PegBio: INED Resignation Triggers Temporary Rule Breach; New Candidate Nominated to Restore Compliance
PegBio independent director Fan resigns, audit committee chair role to change
Reuters  ·  05-19
PegBio independent director Fan resigns, audit committee chair role to change
Stock Track | PegBio Soars 28.96% Intraday on Exclusive GLP-1 Drug Commercialization Deal
Stock Track  ·  05-19
Stock Track | PegBio Soars 28.96% Intraday on Exclusive GLP-1 Drug Commercialization Deal
PEGBIO CO-B (02565) Surges 150% in Late Trading Following Exclusive Commercial Deal for Padakine in Mainland China
Stock News  ·  05-18
PEGBIO CO-B (02565) Surges 150% in Late Trading Following Exclusive Commercial Deal for Padakine in Mainland China
Registration Open for "Zhihui Financial 2026 Summer Roadshow Conference"
Stock News  ·  05-18
Registration Open for "Zhihui Financial 2026 Summer Roadshow Conference"
PegBio Reports No Share Capital Changes in April 2026; Public Float Remains Compliant
Bulletin Express  ·  05-06
PegBio Reports No Share Capital Changes in April 2026; Public Float Remains Compliant
Stock Track | PEGBIO CO-B Soars 18.91% Intraday as Cornerstone Investors Extend Lock-Up Period, Signaling Strong Confidence
Stock Track  ·  05-05
Stock Track | PEGBIO CO-B Soars 18.91% Intraday as Cornerstone Investors Extend Lock-Up Period, Signaling Strong Confidence
PEGBIO Shares Surge Nearly 19% on Extended Lock-Up Period Demonstrating Long-Term Confidence
Stock News  ·  05-05
PEGBIO Shares Surge Nearly 19% on Extended Lock-Up Period Demonstrating Long-Term Confidence
No data available

Introduction

Company Name.
PEGBIO CO-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
PegBio Co Ltd is a China-based company principally engaged in the discovery and development of innovative therapies. The Company's main product PB-119, is a self-developed, near-commercialized, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The Company's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309. The Company's products are mainly used to treat chronic and metabolic diseases, including type 2 diabetes mellitus (T2DM, also known as type 2 diabetes), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC, a gastrointestinal disorder induced by the usage of opioid drugs) and congenital hyperinsulinemia (a rare endocrine disease whose patients experience constant hypoglycemia).
Issue price:
--